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PBiomarkers
Myeloperoxidase and C-Reactive Protein
Have Combined Utility for Long-Term Prediction of
Cardiovascular Mortality After Coronary Angiography
Claire L. Heslop, BMSC, Jiri J. Frohlich, MD, John S. Hill, PHD
Vancouver, British Columbia, Canada
Objectives We evaluated the relative and combined value of oxidative stress biomarkers for predicting cardiovascular mor-
tality in patients undergoing selective coronary angiography.
Background Oxidative stress participates in all stages of cardiovascular disease, from lipoprotein modification to plaque rup-
ture, and biomarkers of oxidative stress predict development of coronary artery disease (CAD). Oxidative stress
biomarkers merit investigation for the value they may offer for long-term cardiovascular risk prediction.
Methods Myeloperoxidase (MPO), nitrotyrosine, oxidized low-density lipoprotein, and antioxidant capacity were measured in a
prospective cohort of 885 selective coronary angiography patients followed up for13 years for cardiovascular mortality.
Results MPO independently predicted CAD, and top tertile MPO levels predicted a 2.4-fold risk of cardiovascular mortal-
ity (95% confidence interval [CI]: 1.47 to 2.98), compared with patients with lowest tertile MPO levels. MPO also
improved risk model discrimination and patient risk category classification. Elevations in multiple oxidative
stress biomarkers predicted increased mortality risk; however, the strongest risk prediction was achieved by as-
sessing MPO and C-reactive protein (CRP) together. Patients with either MPO or CRP elevated had 5.3-fold
higher cardiovascular mortality risk (95% CI: 1.86 to 14.9), and patients with high levels of both MPO and CRP
had a 4.3-fold risk compared with patients with only elevated marker (95% CI: 2.26 to 8.31). These results re-
mained significant with adjustment for cardiovascular risk factors and baseline disease burden.
Conclusions MPO accurately predicted cardiovascular mortality risk in coronary angiography patients. Considering MPO and
CRP together may improve long-term risk assessment and CAD patient outcomes. (J Am Coll Cardiol 2010;55:
1102–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.050P
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matients with stable coronary artery disease (CAD) require
ngoing effective risk stratification; however, there remain
ignificant clinical limitations to current treatment strategies
1). Biomarkers that add incremental data to cardiovascular
isk prediction have been studied with the goal of enhancing
pproaches to long-term risk reduction (2).
Based on evidence that oxidative stress is involved in all
tages of atherosclerosis (3), oxidative stress biomarkers have
een investigated for their potential clinical value. Oxidative
odifications of low density lipoproteins and cellular lipids
ontribute to vascular endothelium dysfunction (4), monocyte
nvasion (5), foam cell formation (6), and plaque instability (7).
rom the Atherosclerosis Specialty Laboratory, James Hogg iCAPTURE Centre for
ardiovascular and Pulmonary Research, Providence HeartLung Institute, Depart-
ent of Pathology and Laboratory Medicine, University of British Columbia-St.
aul’s Hospital, Vancouver, British Columbia, Canada. This study was supported by
grant from Heart and Stroke Foundation of British Columbia and Yukon,
ancouver, British Columbia, Canada. Recruitment of study participants was funded
y the Canadian Institutes of Health Research, Ottawa, Ontario, Canada.i
Manuscript received July 22, 2009; revised manuscript received October 26, 2009,
ccepted November 9, 2009.ro-oxidant enzyme myeloperoxidase (MPO) is released by
ctivated neutrophils and macrophages. MPO has been found
o predict cardiovascular disease development (8,9) and myo-
ardial infarction in patients with chest pain (10). Nitrotyrosine
N-tyr), a protein residue modification generated byMPO and
eactive nitrogen processes, has been localized to atheroscle-
otic plaques (11), and predicts presence of CAD (12). Ele-
ated plasma oxidized low-density lipoprotein (oxLDL) pre-
icts CAD and severity of acute coronary syndromes (13).
espite this compelling evidence, the prognostic utility of
xidative stress biomarkers for long-term risk assessment in
table CAD has not yet been explored. Finally, circulating
ntioxidant enzymes and molecules may protect against oxida-
ive stress. Indeed, reduced plasma antioxidant capacity (AOC)
s associated with coronary artery calcification (14), but has not
et been demonstrated to predict disease development or
utcome.
Oxidative stress biomarkers that identify instability in CAD
ay be useful for screening stable CAD patients to identifyndividual patients requiring more aggressive interventions.
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March 16, 2010:1102–9 Myeloperoxidase and Cardiovascular Mortalitymproved risk prediction would permit uptitration of medical
herapy and improved compliance in higher-risk patients, and
biomarker that could further guide treatment strategies
ould optimize patient outcome.
On the basis of the preceding evidence, we evaluated
hether plasma oxidative stress biomarkers, separately and in
ombination, predict future fatal cardiovascular events in a
arge, prospective cohort of nonemergent coronary angiogra-
hy patients.
ethods
oronary angiography cohort. Between 1992 and 1995, a
ohort of 1,117 patients (797 men and 320 women) was
ecruited from consecutive selective coronary angiography
ubjects at 2 Vancouver teaching hospitals. Indications for
ngiography included stable angina and previous myocardial
nfarction (MI), as well as aortic stenosis and/or regurgita-
ion, and mitral valve regurgitation. Patients with unstable
ngina and/or MI within the preceding 2 months were
xcluded (n  98). Analyses of this cohort by investigators
n our research group are reported elsewhere (15,16). Le-
ions visualized in major epicardial vessels were assessed
emiquantitatively for percent stenosis, rounded to the
earest 10%. Presence of CAD was defined by the presence
f any lesion 20% stenosis, and severe CAD was defined
y presence of any lesion 50% stenosis.
atient characteristics. Data regarding cigarette smoking
istory (past, current, or never), self-identified ethnicity,
revious diagnosis of hypertension, previous diagnosis of
iabetes mellitus, and history of premature CAD in pa-
ient’s family (males before 45 years of age and females
efore 55 years of age), were obtained by self-report. Blood
ressure was also measured, and hypertension classified by
re-existing diagnosis and/or baseline blood pressure
140/90 mm Hg. Height and weight were measured, and
ody mass index calculated. Waist circumference was mea-
ured midway between the iliac crest and the bottom of the
ibcage. Medication use was recorded from patient’s charts.
ll participants gave written informed consent, and the
esearch Ethics Board of St. Paul’s Hospital, Vancouver,
pproved this research.
ortality data. Identifying data were linked to the British
olumbia Vital Statistics Agency mortality database to
etermine deaths to the end of 2007. Cardiovascular deaths
ere identified by World Health Organization Interna-
ional Classification of Disease-10th revision mortality
odes I20 to I25 and I60 to I69 (17).
iochemical analysis. Fasting blood samples were col-
ected before angiography in ethylenediamine tetra-acetate
acutainer tubes (Becton Dickinson, Franklin Lakes, New
ersey). After centrifugation, plasma was aliquoted and
tored at 70°C, with a single freeze-thaw cycle before
iomarker analyses. Lipid and lipoprotein measurements
ere completed immediately, and inflammatory marker
-reactive protein (CRP) was measured in 2002, using tigh-sensitivity methods, as we
ave described previously (16).
The MPO and N-tyr were mea-
ured using solid-phase enzyme-
inked immunosorbent assays (Hy-
ult, Uden, the Netherlands). The
xLDL was measured using a
ompetitive enzyme-linked immu-
osorbent assay (Mercodia, Upp-
ala, Sweden), based onmonoclonal
ntibody 4E6. The AOC was mea-
ured by a colorimetric assay (Alpco,
alem, NewHampshire) on the ba-
is of reaction of sample antioxidants
ith hydrogen peroxide. Assay per-
ormance was assessed by linearity
tudies using dilutions within assay
inear ranges, and samples were
iluted to obtain measurements
ithin assay linear ranges: MPO
.4 to 100 ng/ml; N-tyr 2 to 1,500
mol/l; oxLDL 0.5 to 7.6 U/l; and
OC 130 to 393 mol/l. Intra-
ssay and interassay coefficients of variation were as follows:
PO (7.2%, 7.8%), N-tyr (7.9%, 11.1%), oxLDL (5.4%,
.2%), and AOC (7.4%, 7.5%). All measurements were per-
ormed blinded to patient data, and in duplicate. Stability of
iomarkers in stored plasma was verified by comparing assay
erformance (coefficients of variation and linearity) with results
rom an angiography cohort collected more recently in our
aboratory (n 20 for comparisons).
ormal range of biomarkers. For the purpose of charac-
erizing biomarker assay performance, a group of 78 patients
37 women and 41 men) was selected to represent the
healthiest” controls. These patients reported no history of
ardiovascular disease, hypertension, diabetes, or renal in-
ufficiency, and they had no lesions 10% stenosis at
aseline coronary angiography.
tatistical analyses. Baseline continuous variables are pre-
ented as mean  SE, skewed variables as median (inter-
uartile range [IQR]), and categorical variables as number
percentage). The MPO, N-tyr, AOC, and CRP had
kewed distribution and were therefore log transformed.
aseline characteristics were tested for relationships with
ngiographic CAD and cardiovascular mortality using Stu-
ent t tests for continuous variables, Mann-Whitney rank-
um tests for skewed continuous variables, and chi-square
tatistics for categorical variables. Logistic regression models
ere used to calculate odds ratios (ORs) and corresponding
onfidence intervals (CIs) for associations between bio-
arkers and angiographic CAD, with adjustment for
he following cardiovascular risk factors: age, sex, total
holesterol/high-density lipoprotein cholesterol ratio (TC:
DL-C), body mass index, smoking, diabetes, and hyper-
Abbreviations
and Acronyms
AOC  antioxidant
capacity
CAD  coronary artery
disease
CI  confidence interval
CRP  C-reactive protein
HR  hazard ratio
IQR  interquartile range
LVEF  left ventricular
ejection fraction
MPO  myeloperoxidase
NRI  net reclassification
index
N-tyr  nitrotyrosine
oxLDL  oxidized low-
density lipoprotein
TC:HDL-C  total
cholesterol/high-density
lipoprotein cholesterol ratioension. These covariates were chosen for demonstrated
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Myeloperoxidase and Cardiovascular Mortality March 16, 2010:1102–9elationships with cardiovascular risk and oxidative stress
athways.
Biomarker tertiles were defined within the cohort and
ested for association with mortality by log-rank tests.
iomarkers associated with mortality were further tested by
ox proportionate hazards analyses, with adjustment for
isk factors listed above, with further adjustment for CRP
nd severe CAD (50% stenosis), where noted. The
roportionate hazards assumption was confirmed by corre-
ating Schoenfeld residuals with time, and partial residual
lots.
To evaluate biomarkers for risk discrimination, c-statistics
rom time-adjusted receiver-operating characteristic curves
ere generated from survival models with and without
iomarkers (18). Then c-statistics were compared using
onparametric methods for comparing curves generated
rom the same patients (19). Risk model calibration was also
ssessed by Hosmer-Lemeshow statistics (20).
Finally, survival models were assessed for accuracy of
atient risk estimation, using cross-classification tables (21).
atient outcome risk was calculated from covariate adjusted
odels, classified into categories of 5%, 5% to 10%, 10%
o 20%, and 20% risk. Rates of patient reclassification
ith biomarkers were calculated, and significance of model
mprovement was determined by the net reclassification
ndex (NRI), as described by Pencina et al. (22). Although
hey do not adjust for right censoring, NRI analyses permit
isk models to be compared for how accurately they predict
n outcome at a given follow-up time.
Baseline Characteristics of Selective Coronary ATable 1 Baseline Characteristics of Selectiv
Angiograph
No (n  1
Age, yrs 58.0 0.
Male, % 53.3
Smoking status, %
Never smoked 44.6
Former or current smoker 55.4
Hypertension, % 55.6
Diabetes mellitus, % 9.4
Family history of CAD, % 52.2
Body mass index, kg/m2 27.4 0.
Waist circumference, cm 86.8 2.
Lipid variables
LDL cholesterol, mg/dl 145 1.
HDL cholesterol, mg/dl 39 0.
TC:HDL cholesterol ratio 5.32 0.
C-reactive protein, mg/l 1.54 [0.72–4
Oxidative stress biomarkers
Myeloperoxidase, ng/ml 80.4 [57.9–1
Nitrotyrosine, nmol/l 71.9 [59.5–9
Oxidized LDL, mU/l 70.4 [58.8–8
Antioxidant capacity, mol/l 286.8 [265.5–
Coronary artery disease (CAD) is defined as any lesions20% stenosis
SE, %, or median [interquartile range].
HDL  high-density lipoprotein; LDL  low-density lipoprotein: TC  total cData were analyzed using SPSS version 14.0 (SPSS Inc.,
hicago, Illinois), and R version 2.8.1 (R Foundation for
tatistical Computing, Vienna, Austria), with 2-tailed
values 0.05 considered statistically significant.
esults
iomarkers and angiographic CAD. Of the patients
ecruited, 885 had samples available for biomarker measure-
ent. Of those patients, 651 had angiographic CAD, and
04 had severe lesions (50% stenosis). Baseline character-
stics are presented in Table 1. Patients with severe lesions
ad higher MPO (p  0.022), oxLDL (p  0.031), and
OC (p  0.003). The oxLDL and AOC were not
ssociated with CAD in age- and sex-adjusted risk models.
owever, MPO predicted angiographic CAD (OR per SD:
.97, 95% CI: 1.08 to 3.60; p 0.03) and severe CAD (OR
er SD: 1.85, 95% CI: 1.09 to 3.18; p  0.021) in covariate
djusted analyses. Oxidative stress biomarker levels among
he 78 healthiest control patients were as follows: median
PO 76.9 (IQR 55.3 to 124.7), N-tyr 76.6 (IQR 66.4 to
8.9), oxLDL 65.7 (IQR 54.3 to 82.1), and AOC 287.9
IQR 263.8 to 314.0).
iomarkers and baseline characteristics. Female patients
ad lower AOC; median was 280.2 mol/l (IQR 256.1 to
03.7 mol/l) for women versus 302.7 mol/l (IQR 277.7 to
25.7 mol/l) for men (p  0.001), which supports findings
eported elsewhere (23). No other sex differences were
bserved for biomarkers. No ethnicity differences were
ested, as 87% of patients reported Caucasian ethnicity.
graphy Cohortronary Angiography Cohort
ence of Coronary Artery Disease
p ValueYes (n  705)
61.7 0.41 0.001
81.7 0.001
25.0 0.001
75.0
65.3 0.129
20.3 0.001
58.1 0.174
28.2 0.19 0.073
93.6 0.97 0.004
137 1.6 0.007
36 0.4 0.001
5.87 0.08 0.002
1.84 [0.88–5.15] 0.030
92.0 [61.9–138.0] 0.036
72.1 [59.5–88.4] 0.965
72.4 [60.9–89.8] 0.070
] 300.2 [273.3–323.0] 0.006
eline selective coronary angiography. Data are presented as meanngioe Co
ic Evid
80)
91
36
13
2
8
14
.04]
23.6]
0.2]
2.8]
314.0
on basholesterol.
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March 16, 2010:1102–9 Myeloperoxidase and Cardiovascular MortalityAntioxidant capacity correlated with body mass index
r  0.149; p  0.001), as did oxLDL (r  0.173; p 
.001), which supports previous research (24). Higher
xLDL levels were observed in patients with a smoking
istory versus nonsmokers (73.4 mU/l [IQR 61.8 to 91.0
U/l] vs. 70.9 mU/l [IQR 58.7 to 85.6 mU/l]; p  0.03);
owever, these patients also had higher AOC (301.3 mol/l
IQR 274.3 to 328.4 mol/l] vs. 295.2 mol/l [IQR 268.6 to
14.7 mol/l]; p  0.01). CRP correlated with MPO (r 
.140; p  0.001), as observed elsewhere (25).
Patients with angiographic CAD were more likely to
eport statin use at the time of initial assessment (19% vs.
%; p  0.001); however, statin users did not have different
ates of cardiovascular mortality (hazard ratio [HR]: 0.96
95% CI: 0.59 to 1.67]). Although patients with angio-
raphic disease were not more likely to report using anti-
ypertensive medications at baseline, use of angiotensin-
onverting enzyme inhibitors predicted cardiovascular
ortality (HR: 2.54 [95% CI: 1.73 to 3.74]; p 0.001). No
ther class of medication was associated with mortality, and
o differences in biomarkers were observed according to
edication use at baseline.
iomarkers and cardiovascular mortality. After a median
ollow-up time of 12.9 years (IQR 11.1 to 13.1 years), there
ere 257 deaths, and 117 were cardiovascular deaths.
atients who died of cardiovascular causes were older (p 
.001), and more likely to have diabetes (p  0.026). Also,
hey had higher TC:HDL-C (p  0.001), CRP (p 
.001), and MPO (p  0.001).
Risk for cardiovascular mortality increased across tertiles
f MPO (p  0.007) and N-tyr (p  0.029) (Fig. 1), with
ignificant differences between highest and lowest tertiles
ppearing within the first year for MPO, and after 4 years
or N-tyr. Risk for cardiovascular mortality among patients
ith severe CAD also increased across tertiles of MPO (p
.029) and N-tyr (p  0.035). Adjustment for covariates
ttenuated relationships between N-tyr and cardiovascular
ortality (Table 2).
The unadjusted HR for cardiovascular mortality for the
op MPO tertile was 2.38 (95% CI: 1.47 to 2.98) compared
ith the bottom tertile (p 0.001). The risk remained with
ovariate adjustment (HR: 1.96, 95% CI: 1.15 to 3.37; p 
.012). With further adjustment for severe CAD (50%
tenosis) the risk remained high (HR: 2.06, 95% CI: 1.26 to
.36; p  0.004).
Finally, the risk for elevatedMPO remained significant with
urther adjustment to include CRP (HR: 1.75, 95%CI: 1.16 to
.10; p 0.010), and althoughCRP attenuated the risk for the
econd tertile, the trend remained linear (p 0.036). Survival
nalyses for MPO are displayed in Table 3.
Left ventricular ejection fraction (LVEF) values were
ollected from coronary angiography reports for a subset
f angiography patients (n  415). Decreased LVEF was
ssociated with cardiovascular mortality (p  0.001), but
VEF did not correlate with oxidative stress biomarkers.
In covariate adjusted survival analyses including adjust- pent for CAD severity, CRP, and LVEF, risk associated
ith the highest MPO tertile remained strong (HR: 2.88,
5% CI: 1.18 to 7.03; p  0.02), and the trend remained
inear across tertiles (p  0.030).
In covariate-adjusted survival analyses including adjust-
ent for CAD severity, CRP, and use of angiotensin-
onverting enzyme inhibitors at baseline, risk associated
ith the highest MPO tertile remained strong (HR: 2.02,
5% CI: 1.22 to 3.34; p  0.001), and the trend remained
inear (p  0.022).
ombined biomarkers and cardiovascular mortality
isk. Oxidative stress scores, assigned by adding the num-
er of pro-oxidant markers (MPO, N-tyr, and oxLDL) in
he highest tertile with a score for AOC in the lowest tertile,
Figure 1 Survival Curves for Cardiovascular
Mortality by MPO and N-tyr Tertiles
Cumulative survival curves for cardiovascular mortality by tertiles of myeloper-
oxidase (MPO) (A) and nitrotyrosine (N-tyr) (B). Blue lines indicate lowest
biomarker tertile, green lines indicate second tertile, and red lines indicate
third (highest) tertile. Log-rank test: MPO p  0.007, N-tyr p  0.029.redicted cardiovascular mortality in a linear fashion (p 
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Myeloperoxidase and Cardiovascular Mortality March 16, 2010:1102–9.010). Patients with the highest scores (3 and 4, n  89)
ad a 2.8-fold cardiovascular mortality risk (95% CI: 1.53 to
.39; p  0.001) compared with patients who had the
owest multimarker score (n  262). This relationship
ersisted with adjustment for covariates and severity of
AD (p  0.037 for linear trend). However, the trend was
ttenuated by adjustment for MPO, suggesting multiple
arkers offered no significant benefit.
ombined value of MPO and CRP. The CRP tertiles
ere defined within the cohort as 1.04, 1.04 to 3.30,
nd 3.30 mg/l. MPO not only predicted cardiovascular
ortality independent of CRP, but also combining MPO
nd CRP tertiles predicted cardiovascular mortality risk
azard Ratios for Cardiovascular Mortalityy Tertiles f Nit oty osineTable 2 Hazard Rat os for Cardi v scular Mortalityby Tertiles of Nitrotyrosine
Variable
Tertile (Range), nmol/l
p Value1 (<63.9) 2 (63.9–82.5) 3 (>82.5)
Patients, n 295 295 294
Cardiovascular
deaths, n (%)
29 (9.8) 45 (14.2) 43 (15.6)
Unadjusted
Hazard ratio 1.0 1.87 1.66 0.05
95% CI — 1.15–3.13 0.98–2.79
p value — 0.018 0.06
Adjusted for risk
factors*
Hazard ratio 1.0 1.83 1.47 0.08
95% CI — 1.09–3.09 0.89–2.50
p value — 0.023 0.10
Covariate adjustment for age, sex, total/high-density lipoprotein cholesterol ratio, body mass
ndex, smoking, diabetes, and hypertension.
CI  confidence interval.
Hazard Ratios for Cardiovascular Mortality by TeTable 3 Hazard Ratios for Cardiovascular M
1 (<70.2)
Patients, n 295
Cardiovascular deaths, n (%) 24 (8.1)
Unadjusted
Hazard ratio 1.0
95% CI —
p value —
Adjusted for risk factors*
Hazard ratio 1.0
95% CI —
p value —
Further adjusted for CAD severity†
Hazard ratio 1.0
95% CI —
p value —
Further adjusted for C-reactive protein‡
Hazard ratio 1.0
95% CI —
p value —
*Covariate adjustment for age, sex, total/high density lipoprotein chole
adjusted for 50% stenosis on baseline coronary angiography. ‡Further adju
CAD  coronary artery disease; CI  confidence interval.p  0.001). Patients who had either marker elevated had
5.33-fold risk of cardiovascular mortality compared
ith patients who had both biomarkers in the lowest
ertile (95% CI: 1.86 to 14.9; p  0.002). Patients who
ad both markers elevated had a 4.33-fold risk of
ardiovascular mortality compared with patients who had
ither biomarker elevated (95% CI: 2.26 to 8.31; p 
.001). Cumulative survival curves for this comparison
re displayed in Figure 2.
These observations remained significant after covariate
djustment, including adjustment for either CRP or MPO
evels. Among patients with severe CAD, covariate adjusted
R was 3.83 for elevation of 1 marker (95% CI: 1.33 to
1.02; p 0.013), and 6.41 for both markers (95% CI: 2.18
o 18.78; p  0.001) compared with low levels of both
arkers. Further adjustment for LVEF did not attenuate
he relationship.
valuation of survival models. The covariate adjusted
odel including CAD severity yielded an area under the
urve of 0.715, which improved to 0.761 with MPO (p 
.031), and to 0.781 with combined MPO and CRP tertiles
p  0.004). No deviations from risk calibration were
etected for any risk models.
Finally, covariate adjusted models (including CAD sever-
ty) were used to classify patients into risk categories for
ardiovascular mortality across the entire study duration.
he NRI was calculated from patient reclassification rates
onferred by biomarkers. Patients reclassified by MPO are
isplayed in Table 4. The MPO tertiles improved risk
rediction across all categories, with a NRI of 14.4% (p 
.003). Combining MPO and CRP tertiles also improved
of Myeloperoxidasety by Tertiles of Myeloperoxidase
Tertile (Range), ng/ml
p Value2 (70.2–118.7) 3 (>118.7)
295 295
40 (13.6) 53 (18.0)
1.80 2.38 0.001
1.08–2.98 1.47–2.98
0.023 0.001
1.84 1.96 0.014
1.07–3.14 1.16–3.24
0.026 0.012
1.52 2.06 0.014
0.91–2.55 1.26–3.36
0.110 0.004
1.41 1.75 0.036
0.84–2.37 1.16–3.10
0.194 0.011
atio, body mass index, smoking, diabetes, and hypertension. †Furtherrtilesortali
sterol r
sted for log-transformed C-reactive protein.
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March 16, 2010:1102–9 Myeloperoxidase and Cardiovascular Mortalityatient risk classification over risks estimated by covariates
nd CRP alone (NRI 9.6%; p  0.05).
iscussion
PO has been localized to human atherosclerotic lesions,
nd implicated in proatherogenic modifications to lipopro-
Figure 2 Survival Curves for Cardiovascular
Mortality by Elevations of MPO and CRP
Cumulative survival curves for cardiovascular mortality according to elevations
of myeloperoxidase (MPO) and C-reactive protein (CRP). Patients with lowest
tertile MPO and CRP (blue line) are compared with patients with highest tertile
levels of either marker (green line), and patients with highest tertile measure-
ments of both markers (red line). Log-rank test p  0.001 for trend.
Risk Reclassification Table for MyeloperoxidaseTable 4 Risk Reclassification Table for Mye
Risk of Cardiovascular Mortality From
Covariate Adjusted-Risk Models
Reclassified
Myelope
<5%
5%
n 144
Cardiovascular deaths 5
Mortality rate, % 3.5
5%–10%
n 37
Cardiovascular deaths 0
Mortality rate, % 0
10%–20%
n
Cardiovascular deaths
Mortality rate, %
20%
n
Cardiovascular deaths
Mortality rate, %Risk was estimated frommodels adjusted for age, sex, body-mass index, total/hi
and angiographic stenosis 50%.ein particles (26). Also, catabolism of nitric oxide by MPO
ay impair its vasodilatory and anti-inflammatory functions
n the vasculature (27). Indeed, elevated MPO indepen-
ently predicts reduced endothelial function (28), whereas
RP has not been consistently found to do so (29,30). In
his prospective study of 885 coronary angiography patients,
aseline MPO independently predicted cardiovascular mor-
ality beyond traditional risk factors and degree of angio-
raphic stenosis. Furthermore, MPO enhanced survival
odel discrimination and improved patient risk classifica-
ion across meaningful risk categories. Although multiple
arkers of oxidative stress incrementally influenced car-
iovascular mortality risk, the greatest value was offered
y evaluation of MPO. Finally, MPO and CRP had
ndependent and combined predictive value, and im-
roved accuracy of patient risk estimations.
MPO has previously been demonstrated to identify pa-
ients with acute coronary syndromes and MI who are at
igher risk for adverse outcomes (31,32); however, one
tudy found risk conferred by MPO was only for events
uring the initial 72 h after onset of symptoms (33).
lthough elevations of MPO secondary to recruitment
nd activation of neutrophils in ACS may explain these
esults (34), MPO may also be induce plaque rupture by
ctivating metalloproteases (35) and triggering endothe-
ial cell apoptosis (36). Level of MPO is also elevated in
atients with heart failure (37), and may have value for
eart failure screening, in combination with CRP (38).
e demonstrate for the first time the value of MPO for
ong-term risk estimation for patients with stable CAD,
n comparison with traditional risk factors and CRP.
ultiple oxidative stress markers have been associated
ith CAD in a smaller, cross-sectional study (39);
oxidase
f Cardiovascular Mortality With
se Tertiles in Risk Models
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Myeloperoxidase and Cardiovascular Mortality March 16, 2010:1102–9owever, our study is the first prospective investigation of
ultiple oxidative stress biomarkers in angiography pa-
ients. Our findings extend and refine the current evi-
ence implicating oxidative stress in cardiovascular dis-
ase, and we clarify the relative prognostic utility of
xidative stress biomarkers compared with conventional
isk factors.
Not all studies are consistent with our findings. Kubala
t al. (25) did not find elevated MPO in CAD patients, and
recent study of 382 stable CAD patients found MPO did
ot predict total mortality (40). However, we followed up
ur larger cohort of patients for a longer time, and deter-
ined cause for all cases of mortality. Also, we included
atients with moderate lesions, which are more often
mplicated in MI (41). By investigating patients across a
ange of risk, we elucidated the prognostic value of MPO,
nd identified that MPO offers the improvements across
eaningful risk categories—including intermediate catego-
ies for which more challenging therapeutic decisions must
e made, and for which interventional countermeasures
uch as revascularization may reduce cardiovascular mortal-
ty risk. Most important, we demonstrate for the first time
he complementary value of MPO and CRP for identifying
atients at risk for cardiovascular mortality.
tudy limitations. We could not ascertain biomarker
hanges over time, nor could we adjust for baseline renal
unction, a major influence on oxidative stress levels. Be-
ause of limitations inherent to our samples, we were also
ot able to measure and compare our findings with every
merging cardiovascular and oxidative stress biomarker.
ertain data regarding medication use, interventions, and
ther cardiovascular events after initial assessment are also
ot available.
Although there is good evidence from multiple studies
hat MPO has value for risk assessment in cardiovascular
ohorts, the transportability of our results to a more diverse
ohort or to lower risk populations has yet to be shown.
inally, the research grade assays used for these analyses are
ot yet approved for clinical application, and interpretation
f results from different assays must be done with caution.
onclusions
he oxidative stress biomarker MPO powerfully enhances
ardiovascular risk prediction, and is additive with CRP for
redicting risk in selective angiography patients. Future
tudies are essential to demonstrate whether outcomes may
e improved when MPO and CRP measurements are
tilized together for prognostic assessment and therapeutic
ecision making.
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